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of talent to the more funded areas in an already talent-
scarce environment,4 and distorts salaries. The parallel 
systems that are set up (eg, budgeting and procurement) 
and the range of coordination bodies and committees 
that emerge are cumbersome to manage, especially in 
view of the limited internal capabilities in the country.
The diﬀ erent reporting and timing requirements 
increase the burden of monitoring and evaluation, 
which is acutely felt at the district level where the lone 
doctor or nurse has to respond to multiple demands in 
diﬀ erent formats.1 A substantial part of the resources is 
usually used to pay expatriates’ salaries, which are far 
higher than local salaries, and it is only what is left that 
gets to be spent on the diseases.
I am concerned about the choice of country receiving aid 
funds for health. Health aid should be coordinated so that 
all people in need would beneﬁ t no matter which African 
country one lives in. But we ﬁ nd so many organisations 
and initiatives focused in a few African countries, with 
many of them in a single country. The reason for the 
choice of country is not always clear: are the organisations 
following past colonial links? Are they choosing countries 
that have shown a positive track record of addressing their 
health challenges? Are they supporting governments that 
have been active in ﬁ ghting corrupt practices? What is clear 
is that they are not always present in the countries that 
need them the most. Global health governance should, in 
a way, ignore geographical boundaries. True, one would 
always want to target countries where the likelihood of 
impact is the highest. Countries that currently fall short 
should be helped to attain a level from where they can 
also perform and show impact.
There is urgent need for a mechanism that will enable 
coordination of aid for health at country, regional, and 
global levels, and coordination among partners and 
funders within a speciﬁ c sector. Partner coordination 
should be strengthened at all levels, to avoid duplication 
of eﬀ orts, improve eﬃ  ciency, and ensure that country 
priorities are respected. The result would be better 
harmonisation, transparency, accountability, better 
implementation of programmes, and a fair and even 
attribution of resources within a country, so that 
countries can better move forward towards attaining 
the Millennium Development Goals.1,5,12
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In The Lancet today, Rebeccah Slater and colleagues1 
present a randomised trial in which they evaluated 
sucrose as an analgesic in newborn babies. The cortical 
evoked responses that they recorded from newborn 
babies treated with sucrose or sterile water were 
similar. They concluded that sucrose “might not be an 
eﬀ ective analgesic drug”, but we think their conclusion 
is premature.
Slater and colleagues’ research is a laudatory mix 
of innovative research on cortical evoked responses 
to noxious stimulation and a rigorous randomised 
trial. However, evolving measurement methodologies 
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and small sample sizes are not the basis for deﬁ nitive 
evaluations of treatments. The results of initial small 
randomised trials are often not replicated by larger 
deﬁ nitive randomised trials.2,3
Although the investigators recorded cortical evoked 
responses to a heel lance, those responses probably do 
not reﬂ ect activation of the neural pain pathway in its 
entirety. Slater and colleagues sampled a limited set of 
brain activity, both spatially and temporally; the spatial 
component was restricted to a single electrode location, 
and temporally they restricted their sampling to 1 s 
after stimulus onset within the electroencephalogram 
(EEG) frequency band. The EEG traces were further 
processed with a Woody ﬁ lter, signal averaging, and 
principal component analysis. In previous work, Slater 
and colleagues applied the same technique to a set of 
12 electrodes and showed that the weight of the ﬁ rst 
principal component for temporal electrode T3 and 
the weights of the second principal component for 
central locations Cz and CPz related to the presence of 
noxious stimuli.4 They subsequently focused on both 
central electrodes, and in today’s study they limited 
this procedure further to activity at Cz and the second 
principal component. Multichannel EEG recordings 
associated with signal decomposition and source 
localisation procedures might provide an improved 
basis for the localisation of relevant circuitry, and 
consequently for the selection of signals and metrics 
that represent nociception.5 In today’s approach, sucrose 
might modulate the activity of components of the pain 
pathway that Slater and colleagues did not measure.
Slater and colleagues’ study was powered to detect 
only a very large sucrose-induced reduction in cortical 
evoked responses. Standardised eﬀ ect sizes (in this 
study, the diﬀ erence in mean weights of the second 
principal component in the two treatment conditions 
divided by the pooled standard deviation [SD]) are used 
in sample size calculations when the primary outcomes 
are not intrinsically meaningful, such as in this study. 
This study was powered to detect a standardised eﬀ ect 
size of 0·9 SDs, a very large eﬀ ect size by any standard, 
including Cohen’s classiﬁ cation.6 There was only a one in 
three chance of detecting a medium eﬀ ect size (0·5 SDs) 
and a discouraging one in ten chance of detecting a 
small eﬀ ect size (0·2 SDs). Therefore we should not 
be surprised that the study failed to detect an eﬀ ect 
of sucrose on cortical evoked responses. Small sample 
sizes also increase concerns that treatment–condition 
imbalances, despite random allocation, could account 
for the study’s results.
A more deﬁ nitive evaluation of sucrose as an analgesic 
requires a larger study that follows guidelines for 
interpretable randomised trials, as articulated in the 
CONSORT Statement.7 The results of a deﬁ nitive study 
also need to be generalised to sick and preterm newborn 
babies at risk for multiple painful procedures over 
extended stays in the hospital.
Slater and colleagues characterise the cortical evoked 
responses that they recorded as a more direct measure 
than other responses used to measure pain in newborn 
babies. But it is the wellbeing of the infant that is the 
deﬁ nitive outcome in determining the eﬃ  cacy of 
medical interventions and not surrogate outcomes, 
regardless of how central they are hypothesised to 
be to the pain response in the newborn baby. There 
are noteworthy examples of interventions that aﬀ ect 
compelling surrogate outcomes but fail to improve 
and might even adversely aﬀ ect the health status of 
patients.8,9 The opposite result is possible as well.
Despite the limitations outlined above, Slater and 
colleagues’ study adds an important and innovative 
Criteria for interpretable study results Extent that criteria were met by Slater and colleagues’ study
Study designed, executed, and presented 
according to Consort Statement7
Yes, with noted modiﬁ cation of primary outcome
Clinically relevant intervention Sucrose dosing was not evaluated but is in accord with current 
clinical practice
Signal acquisition and processing Limited in spatial (Cz ) and temporal domains (1 s window of 
EEG, bandwidth 0·5–70 Hz); dimensionality was reduced by 
principal component analysis
Validity of outcome Authors have not demonstrated that primary outcome is the 
necessary and suﬃ  cient measure of pain as assumed by their 
conclusion
Adequacy of outcome Outcome is component of cortical evoked response to heel 
lance; short-term and long-term clinical consequences were not 
evaluated
Adequate sample size Study was powered to detect only large eﬀ ects of sucrose 
(0·9 standard deviations)
Adequate sample characteristics Sample was convenience sample; generalising results to all 
newborn babies and especially those at high risk for painful 
procedures is important
Exchangeability of cases in the two 
treatment conditions
Concerns about imbalances between treatment conditions 
increase in small samples despite random allocation, and 
demonstrated comparability on measured variables (table 1 in 
the paper); additionally, we do not know whether adjusting 
response to noxious stimulus by diﬀ erences in response to 
non-noxious stimulus as measure of cortical evoked 
responsiveness would alter results
Replicated results No
Table: Support for Slater and colleagues’ conclusion that sucrose “might not be an eﬀ ective analgesic drug”
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Acute coronary syndromes: ﬁ nding meaning in OASIS 7
Acute coronary syndromes typically arise from rupture of 
a cholesterol-laden plaque with subsequent thrombotic 
occlusion of the coronary artery. Whether the vessel 
stays occluded or is recanalised—either by the body’s 
endogenous ﬁ brinolytic system or by external incursion 
(most commonly, percutaneous coronary intervention 
[PCI])—determines the extent of myonecrosis and 
eventual prognosis. An early invasive strategy with 
PCI can reduce death, myocardial (re)infarction, and 
recurrent ischaemia in acute coronary syndromes.1,2 
In view of the central role of the platelet in coronary 
thrombosis, and heightened platelet activation after PCI, 
antiplatelet agents are crucial for the management of 
these syndromes. For more than a decade, the mainstay 
of antiplatelet therapy has been the combination of the 
cyclo-oxygenase inhibitor aspirin, and the ADP-receptor 
antagonist clopidogrel. The limitations of clopidogrel have 
been extensively documented. Clopidogrel is a prodrug 
that is hydrolysed and oxidised to its active metabolite, 
is prone to drug–drug interactions, has a slow onset of 
action, and has a modest antiplatelet eﬀ ect. A substantial 
minority of patients are hyporesponsive to a standard 
300 mg load and 75 mg daily dose.3 High doses more 
rapidly achieve greater peak eﬀ ects than do low doses, 
although many patients remain hyporesponsive to even a 
600 mg load and 150 mg daily dose, and are predisposed 
to adverse cardiovascular events.4 Other patients are 
exquisitely sensitive to clopidogrel, and have a greater 
propensity for haemorrhagic complications.5 Because 
ischaemia and bleeding are strongly related to mortality,6 
optimum dosing of aspirin and clopidogrel is crucial.
The CURRENT-OASIS 7 investigators,7 reporting in 
The Lancet today, have accomplished a remarkable 
achievement in completing a 2×2 factorial randomised 
trial of clopidogrel (standard dose: 300 mg load 
and 75 mg per day vs double dose: 600 mg load and 
150 mg per day for 6 days and then 75 mg per day) and 
aspirin (300–325 mg vs 75–100 mg per day) in just over 
25 000 patients with acute coronary syndromes who were 
intended for an early invasive strategy. 17 233 went on 
to have a PCI. By intention-to-treat analysis in the larger 
study population (PCI and no PCI), both the aspirin and 
clopidogrel randomisations led to neutral results (ie, did 
not reach statistical signiﬁ cance for the 30-day primary 
composite endpoint of cardiovascular death, myocardial 
infarction, or stroke8). Major bleeding was increased in 
the double-dose clopidogrel group,8 which suggests that 
this regimen might be less clinically desirable than the 
standard-dose clopidogrel regimen; but the devil is in the 
details. After diagnostic angiography, 69% of patients had 
PCI. Double-dose clopidogrel, however, was continued 
even in patients undergoing medical therapy (many of 
whom had no signiﬁ cant coronary artery disease), and 
after bypass-graft surgery, in which the usefulness of even 
low-dose clopidogrel is uncertain. As a result, in today’s 
paper, a signiﬁ cant interaction (p=0·026) was present, 
measurement to evaluating pain management in new-
born babies. Such research has just begun but promises 
better understanding of pain and more eﬀ ective pain 
management. However, until we better understand pain 
pathways and the short-term and long-term sequelae 
of painful procedures, it seems premature to conclude 
that sucrose might not be an eﬀ ective analgesic for 
newborn babies.
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